BioMedNewsBreaks

TuesdayMar 03, 2026 10:40 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates

TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc., obtaining rights to develop three drug candidates — UIO-524, UIO-525 and UIO-526 — including all in-licensed and owned rights held by Unleash. Under the agreement, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock, convertible into an equal number of common shares and representing 6.8% of TransCode’s common stock on a fully diluted basis. The lead candidate, UIO-524, is a next-generation oncolytic adenovirus engineered to selectively replicate in malignant…

Continue Reading

TuesdayMar 03, 2026 9:50 am

BioMedNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Acquires 19.99% Stake in America First Defense to Expand AI-Driven Defense Portfolio

Gaxos.ai (NASDAQ: GXAI) announced it has acquired a 19.99% stake in America First Defense, a U.S.-based defense technology company developing next-generation drone and robotics platforms across air and ground domains. America First Defense is focused on a detachable counter-drone system designed to neutralize hostile UAVs through precise protocol-level cyber attacks and a biomimetic soft robotics platform engineered for low-detection ground and subsurface operations, targeting demand from U.S. defense, homeland security, border security, maritime security, municipal safety and critical infrastructure operators. Gaxos said the investment expands its exposure to American-owned defense innovation and aligns with its strategy to build a diversified…

Continue Reading

MondayMar 02, 2026 9:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

Continue Reading

MondayMar 02, 2026 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a psychiatrist, neurologist and neuroscientist who studies the mechanisms of Transcranial Magnetic Stimulation (TMS) and their translation into clinical optimization. He serves as Medical Director of the McLean Hospital TMS Service, Director of TMS research and founding director of the Brain Stimulation Mechanisms Laboratory, with more than $20 million in federal funding from the National Institute of Mental Health and the Defense Advanced Research Projects Agency. At NRx, he will support development of mechanistically informed neuropsychiatric…

Continue Reading

ThursdayFeb 26, 2026 9:27 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease 

Soligenix (NASDAQ: SNGX) announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation of dusquetide, the active ingredient in SGX945, for the treatment of Behçet Disease, following review of recently published Phase 2a data demonstrating biological efficacy and safety. The recommendation now advances to the European Commission for ratification. The company noted that orphan designation in the European Union provides 10 years of market exclusivity upon approval, along with development incentives and centralized authorization access. SGX945 has previously received orphan drug and fast track designations from the U.S. Food and Drug Administration for Behçet Disease. To view the full press release, visit https://ibn.fm/tintJ About Soligenix Inc. Soligenix is…

Continue Reading

ThursdayFeb 26, 2026 9:10 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets

Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival,…

Continue Reading

WednesdayFeb 25, 2026 2:07 pm

BioMedNewsBreaks — Anixa Biosciences, Inc. (NASDAQ: ANIX) CAR-T Co-Inventor To Keynote SCTR 2026 Retreat 

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anixa’s CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026. His remarks are expected to include discussion of Anixa’s ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer first discovered at The Wistar Institute, with the study enrolling women who have progressed after at least two…

Continue Reading

WednesdayFeb 25, 2026 9:30 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Expanded IIA Grant Support for Robotic Aseptic Fill & Finish Platform

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that, following additional review by the Israel Innovation Authority, its project to advance a robotic aseptic fill & finish platform has been approved for expanded support, allowing the company to utilize the full approved grant budget of NIS 5 million over two years, approximately 66% of which is non-dilutive funding. The program supports acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026. The investment supports Scinai’s broader CDMO expansion strategy following its acquisition of Recipharm…

Continue Reading

WednesdayFeb 25, 2026 9:10 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach. To view the full press release, visit https://ibn.fm/TToz2 Tonix Pharmaceuticals…

Continue Reading

WednesdayFeb 25, 2026 9:09 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports Multi-Pillar Clinical and Commercial Progress 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms. The company highlighted submission of a manuscript for peer review, showcasing both a new method, Capture-Seq, and new biomarkers for the detection of cancer, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion. Commercialization of the Nu.Q Cancer assay progressed in lung cancer, with the company reporting reimbursement submission in France on track, and routine clinical use expected by Q4 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis and further highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe. The company…

Continue Reading